Cystatin C in acute kidney injury

Current Opinion in Critical Care

Volumn 16, Issue 6, 2010, Pages 533-539

  Bagshaw, Sean M ^a   Bellomo, Rinaldo ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

acute kidney injury; biomarker; critical illness; cystatin C; glomerular filtration rate; renal replacement therapy; serum creatinine

Indexed keywords

CYSTATIN C;

CRITICALLY ILL PATIENT; ENZYME BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART SURGERY; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; PATIENT SELECTION; PROTEIN SECRETION; PROTEIN URINE LEVEL; REVIEW; STANDARD; STEM CELL TRANSPLANTATION;

ACUTE KIDNEY INJURY; AGE FACTORS; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; CRITICAL ILLNESS; CYSTATIN C; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; KIDNEY FUNCTION TESTS; POSTOPERATIVE COMPLICATIONS; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 78649655413     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32833e8412     Document Type: Review

References (81)

1. Bagshaw SM, George C, Dinu I, Bellomo R. A multicentre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1203-1210. (Pubitemid 351767483)
2. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843.
3. Uchino S, Kellum JA, Bellomo R, et al.Acute renalfailure incriticallyill patients: a multinational, multicenter study. JAMA 2005; 294:813-818.
4. Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302: 1179-1185.
5. Bellomo R, Ronco C, Kellum JA, et al.Acute renalfailure-definition, outcome measures, animal models,fluidtherapyand informationtechnology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-212.
6. Mehta R L, Kellum JA, Shah SV, et al.Acute Kidney Injury Network: reportof an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
7. American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005; 16:1886-1903.
8. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) indiagnosisand prognosisinacutekidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54:1012-1024.
9. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18:904-912.
10. Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199-203.
11. Herget-Rosenthal S, Marggraf G, Husing J, et al. Earlydetection ofacute renal failure by serum cystatin C. Kidney Int 2004; 66:1115-1122.
12. Herget-Rosenthal S, van Wijk JA, Brocker-Preuss M, Bokenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem 2007; 40:946-951.
13. Herget-Rosenthal S, Poppen D, Husing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50:552-558.
14. Grubb A, Simonsen O, Sturfelt G, et al. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218:499-503. (Pubitemid 16147646)
15. Brzin J, Popovic T, Turk V, et al. Human cystatin, a new protein inhibitor of cysteineproteinases.Biochem Biophys Res Commun 1984; 118:103-109.
16. Barrett AJ, Davies M E, Grubb A.The placeof human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun 1984; 120:631-636.
17. Grubb AO. Cystatin C: properties and use as diagnostic marker. Adv Clin Chem 2000; 35:63-99.
18. Kaseda R, Iino N, Hosojima M, et al. Megalin-mediated endocytosisof cystatin Cin proximaltubulecells. Biochem Biophys Res Commun 2007; 357:1130-1134.
19. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007; 40:153-161.
20. Kottgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51:385-394.
21. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N latex cystatin C assay on the Dade Behring nephelometer II system. Scand J Clin Lab Invest 1999; 59:1-8.
22. Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997; 43:1016-1022.
23. Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measure-ment of human cystatin C. Clin Chem Lab Med 1998; 36:859-865.
24. Knight E L,Verhave JC,Spiegelman D, et al. Factorsinfluencing serumcystatin C levels otherthan renal function and the impact on renal function measure-ment. Kidney Int 2004; 65:1416-1421.
25. Macdonald J, Marcora S,Jibani M, et al.GFRestimation using cystatin Cisnot independent of body composition. Am J Kidney Dis 2006; 48:712-719.
26. Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008; 121:341-348.
27. Retnakaran R, Connelly PW, Harris SB, et al. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol 2007; 22:1007-1013.
28. Taleb S, Cancello R, Clement K, Lacasa D. Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology 2006; 147:4950-4959.
29. Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and sub-cutaneous adiposity with kidney function. Clin J Am Soc Nephrol 2008; 3:1786-1791.
30. Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med 2007; 45:1232-1236.
31. Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28:346-349.
32. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47:2055-2059.
33. Rule A D, Bergstralh EJ, Slezak J M, et al.Glomerularfiltration rateestimated by cystatin C among different clinical presentations. Kidney Int 2006; 69:399-405.
34. Kitamura H, Kamon H, Sawa S, et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23:491-502.
35. Demirtas S, Akan O, Can M, et al. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem 2006; 39:115-118.
36. Galteau MM, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001; 39:850-857.
37. Qutb A, Syed G, Tamim HM, et al. Cystatin C-based formula is superior to MDRD, Cockcroft-Gault and Nankivell formulae in estimating the glomerular filtration rate in renal allografts. Exp Clin Transplant 2009; 7:197-202.
38. Grubb A, Bjork J, Lindstrom V, et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than crea-tinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005; 65:153-162.
39. Grubb A, Nyman U, Bjork J, et al.Simplecystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005; 51:1420-1431.
40. Gerhardt T, Poge U,Stoffel-Wagner B, et al. Estimation of glomerularfiltration rates after orthotopic liver transplantation: Evaluation of cystatin C-based equations. Liver Transpl 2006; 12:1667-1672.
41. Poge U, Gerhardt T, Stoffel-Wagner B, et al. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006; 21:660-664. (Pubitemid 43372911)
42. Poge U, Gerhardt T, Stoffel-Wagner B, et al. Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients. Kidney Int 2006; 70:204-210. (Pubitemid 44000140)
43. Poge U, Gerhardt T, Stoffel-Wagner B, et al. Prediction of glomerularfiltration rate in renal transplant recipients: cystatin C or modification of diet in renal disease equation? Clin Transplant 2006; 20:200-205.
44. Poge U, Gerhardt T, Woitas RP. Calculation of glomerularfiltration rate using serum cystatin C in kidney transplant recipients. Kidney Int 2006; 70:1878. (Pubitemid 44684824)
45. Tidman M, Sjostrom P, Jones I. A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant2008; 23:154-160.
46. Menon V, Shlipak M G, Wang X, et al. Cystatin Cas a riskfactorforoutcomes in chronic kidney disease. Ann Intern Med 2007; 147:19-27. (Pubitemid 351664630)
47. Villa P, Jimenez M, Soriano MC, et al. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care 2005; 9:R139-143.
48. Delanaye P, Cavalier E, Depas G, et al. New data on the intraindividual variation of cystatin C. Nephron Clin Pract 2008; 108:c246-c248.
49. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
50. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatininefortheestimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem 2007; 40:383-391.
51. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29-34.
52. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18:2024-2031.
53. Herget-Rosenthal S, Feldkamp T, Volbracht L, Kribben A. Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: preci-sion, interferences, stability and reference range. Ann Clin Biochem 2004; 41:111-118.
54. Nejat M, Pickering JW, Walker RJ, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care 2010; 14:R85.
55. Hoste EA, Cruz DN, Davenport A, et al. The epidemiology of cardiac surgery-associated acute kidney injury. Int J Artif Organs 2008; 31:158-165. (Pubitemid 351425013)
56. Haase M, Bellomo R, Devarajan P, et al. Novel biomarkers early predict the severityofacute kidney injury aftercardiacsurgery in adults. Ann Thorac Surg 2009; 88:124-130.
57. Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery: a pro-spective cohort study. Crit Care Med 2009; 37:553-560.
58. Heise D,Waeschle RM,Schlobohm J, et al. Utility of cystatin Cforassessment of renal function after cardiac surgery. Nephron Clin Pract 2009; 112:c107-c114.
59. Koyner JL, Bennett MR, Worcester EM, et al. Urinary cystatin C as an early biomarkerofacute kidneyinjuryfollowing adultcardiothoracicsurgery. Kidney Int 2008; 74:1059-1069.
60. Laneza M,Andrade RR, Castiglia Y M, et al.Cystatin Cand glomerularfiltration rate in the cardaic surgery with cardiopulmonary bypass. Rev Braz Cir Cardiovasc 2009; 24:305-311.
61. Ristikankare A, Poyhia R, Kuitunen A, et al. Serum cystatin Cin elderlycardiac surgery patients. Ann Thorac Surg 2010; 89:689-694.
62. Wald R, Liangos O, Perianayagam MC, et al. Plasma cystatin C and acute kidney injury after cardiopulmonary bypass. Clin J Am Soc Nephrol 2010; 5:1373-1379.
63. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant 2010. (E-pub 28 March 2010)
64. Perianayagam MC, Seabra VF, Tighiouart H, et al. Serum cystatin C for prediction of dialysis requirement or death in acute kidney injury: a compara-tive study. Am J Kidney Dis 2009; 54:1025-1033.
65. Bell M, Granath F, Martensson J, et al. Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol Dial Transplant 2009; 24:3096-3102.
66. McCullough PA, Stacul F, Becker CR, et al. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med 2006; 7:177-197.
67. Briguori C, Visconti G, Rivera NV, et al. Cystatin Cand contrast-induced acute kidney injury. Circulation 2010; 121:2117-2122.
68. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, et al. Urinary and serum biomarkers aftercardiac catheterization in diabetic patientswith stable angina and without severe chronic kidney disease. Ren Fail 2009; 31:910-919.
69. Merkle M, Sauter M, Argirov M, Wornle M. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine. Ren Fail 2010; 32:85-90.
70. Shaker O, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology 2010. (E-pub 7 June 2010)
71. Frisk P, Arvidson J, Neveus T. Glomerularand tubularfunction inyoung adults treated with stem-cell transplantation in childhood. Pediatr Nephrol 2010; 25:1337-1342.
72. Muto H, Ohashi K, Ando M, et al. Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2010; 91:471-477.
73. Hazar V, Gungor O, Guven A G, et al. Renal function after hematopoietic stem cell transplantation in children. Pediatr Blood Cancer 2009; 53:197-202.
74. Demirtas S, Bozbas A, Akbay A, et al. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311:81-89.
75. Kniepeiss D, Wagner D, Wirnsberger G, et al. Serum cystatin C is an easy to obtain biomarker for the onset of renal impairment in heart transplant reci-pients. J Thorac Cardiovasc Surg 2010. (E-pub 4 May 2010)
76. Szewczyk M, Wielkoszynski T, Zakliczynski M, Zembala M. Plasma neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine, and glomerular filtration rate in patients after heart and lung transplantation. Transplant Proc 2009; 41:3242-3243.
77. Ortiz F, Harmoinen A, Paavonen T, et al. Is cystatin C more sensitive than creatinine in detecting early chronic allograft nephropathy? Clin Nephrol 2008; 70:18-25.
78. Lebkowska U, Malyszko J, Lebkowska A, et al. Neutrophil gelatinase-asso-ciated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant Proc 2009; 41:154-157.
79. Soto K, Coelho S, Rodrigues B, et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol 2010. (E-pub 24 June 2010)
80. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010; 28:463-469.
81. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312-318.